A qualitative study by Nathwani et al [29] investigated adult patients with relapsed and refractory MM (RRMM) who had a life expectancy of ≥3 months and had at least one treatment regimen with a proteasome inhibitor and immunomodulator or a steroid in addition to either a CD38 monoclonal antibody or an alkylating agent. This evidence concerns the gene CD38 and Miyoshi myopathy.